All content for OncoPharm is the property of John Bossaer and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
A Holiday tradition like few other. Are we keeping, regifting, or returning new oncology drugs approved in 2025?
[Moving Trailer Voice] This Halloween: They always come back....
The latest revival is belantamab mafodotin, FDA approved...again. After being vanquished in DREAMM3, it returned in DREAMM7 and even Daratumumab (in combination with Vd) couldn't overcome this blindingly effective drug (in combination with Vd).
This pod reviews belantamab mafodotin's checkered past and wonders what the sequels may have in store for us.
OncoPharm
A Holiday tradition like few other. Are we keeping, regifting, or returning new oncology drugs approved in 2025?
